DiaMedica Therapeutics Inc. (DMAC)

DMAC Biotech / Pharma

BiotechSign Signal Grade

F
Signal Grade
27.1/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Dilution Risk
37
Clinical Activity
38
Short Interest
50

Pipeline Overview

Therapeutic Focus
Biotech / Pharmasrc

Clinical Trial Activity

1
Clinical Trial
(ClinicalTrials.gov aggregate)
1 Phase 2, 1 Phase 3
Trial Phase Breakdown
0
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov

Dilution Risk

MEDIUM DILUTION RISK
18.7 months
Cash Runway Estimate
37/100
Dilution Score
40Warrant Risk
40Convertible Risk
42Offering Ability

Dilution score: 37/100 (MEDIUM), 18.7 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

19.19%
Float Shorted
36.7
Days to Cover
MODERATE
Squeeze Risk
+1.7%
SI Change
STABLE
Trend
5,486,848
Shares Short

Short interest: 19.19% of float, squeeze risk: MODERATE

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for DiaMedica Therapeutics Inc..

Full DMAC Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.